GTS Securities’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$643K Buy
+3,340
New +$360K 0.01% 750
2025
Q2
– Sell
-21,737
Closed -$616K – 1476
2025
Q1
$616K Buy
+21,737
New +$771K 0.03% 589
2024
Q4
– Sell
-102,159
Closed -$6.83M – 3016
2024
Q3
$6.83M Buy
102,159
+59,665
+140% +$5.48M 0.01% 702
2024
Q2
$5.05M Sell
42,494
-59,412
-58% -$7.52M 0.01% 855
2024
Q1
$10.9M Sell
101,906
-40,154
-28% -$4.05M 0.02% 467
2023
Q4
$14.1M Sell
142,060
-13,047
-8% -$1.1M 0.02% 465
2023
Q3
$16M Buy
155,107
+38,023
+32% +$4.24M 0.03% 402
2023
Q2
$14.2M Buy
+117,084
New +$15.6M 0.45% 51

Other funds holding MRNA

GTS Securities's MRNA Position: Q3 2026 in Review

GTS Securities opened a new position in Moderna (MRNA) in Q3 2026: 3,340 shares worth $643K. The stake represents 0.01% of the portfolio and ranks #750 among its holdings. This is a return to the name: GTS Securities previously reported a position in MRNA as recently as Q1 2025.

GTS Securities first reported a position in MRNA in Q2 2023 and has held it in 8 quarters since. The position peaked at $16M in Q3 2023. 1,053 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • GTS Securities held 3,340 shares of Moderna worth $643K as of Q3 2026.
  • Moderna was a new GTS Securities position in Q3 2026.
  • Moderna made up 0.01% of GTS Securities's portfolio in Q3 2026, its #750 holding.
  • GTS Securities first reported a position in Moderna in Q2 2023 and has held it in 8 quarters since.
  • GTS Securities's Moderna position peaked at $16M in Q3 2023.
  • 1,053 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on GTS Securities's 13F filing for Q3 2026, filed 16 Nov 2026.